• China’s NMPA accepted Hansoh Pharma’s BLA for HS-20093 (risvutatug rezetecan) injection in second-line small cell lung cancer.
• Filing targets adults whose disease progressed on platinum-based chemotherapy; acceptance date was Sept. 2, 2026.
• Submission backed by Phase 3 ARTEMIS-008 data; trial met the primary endpoint of overall survival in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 07, 2026, and is solely responsible for the information contained therein.